Agenus Inc. (AGEN)
-NasdaqCM 4.25 
0.01(0.23%) May 17, 4:00PM EDT
| Prev Close: | 4.26 |
|---|
| Open: | 4.21 |
|---|
| Bid: | 3.52 x 100 |
|---|
| Ask: | 4.60 x 3300 |
|---|
| 1y Target Est: | 10.63 |
|---|
| Beta: | 2.29 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.16 - 4.29 |
|---|
| 52wk Range: | 3.37 - 5.99 |
|---|
| Volume: | 134,629 |
|---|
| Avg Vol (3m): | 159,163 |
|---|
| Market Cap: | 120.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AGENUS INC FinancialsEDGAR Online Financials(Fri, May 17)
- AGENUS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons MeetingGlobeNewswire(Wed, May 1)
- AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billionat Seeking Alpha(Mon, Apr 29)
- Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Apr 24)
- Quickly Approaching Biopharma Catalyst Eventsat Seeking Alpha(Wed, Apr 24)
- Q1 2013 Antigenics Inc. Earnings Release - Before Market OpenCCBN(Wed, Apr 24)
- Agenus Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, Apr 24)
- AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 24)
- An Industry Outlook With Analyst Vernon Bernardinoat Seeking Alpha(Mon, Apr 22)
- Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to FollowGlobeNewswire(Thu, Apr 18)
- Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt FinancingGlobeNewswire(Tue, Apr 16)
- AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligationEDGAR Online(Tue, Apr 16)
- Data on ArQule's ARQ 092Zacks(Wed, Apr 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 32.63 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies.
View More